Harvard Bioscience (NASDAQ:HBIO) Stock Price Crosses Below 200-Day Moving Average of $4.07

Harvard Bioscience, Inc. (NASDAQ:HBIOGet Free Report) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.07 and traded as low as $2.77. Harvard Bioscience shares last traded at $2.79, with a volume of 56,748 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th.

View Our Latest Report on Harvard Bioscience

Harvard Bioscience Trading Up 0.4 %

The company has a quick ratio of 0.94, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. The stock has a fifty day simple moving average of $3.23 and a 200 day simple moving average of $4.07. The firm has a market capitalization of $121.17 million, a P/E ratio of -13.95 and a beta of 1.31.

Insider Transactions at Harvard Bioscience

In other news, CEO James W. Green bought 20,000 shares of Harvard Bioscience stock in a transaction dated Thursday, June 6th. The shares were purchased at an average cost of $3.07 per share, with a total value of $61,400.00. Following the completion of the acquisition, the chief executive officer now owns 3,101,091 shares of the company’s stock, valued at approximately $9,520,349.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO James W. Green purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The stock was bought at an average price of $2.91 per share, for a total transaction of $29,100.00. Following the completion of the transaction, the chief executive officer now owns 3,111,091 shares in the company, valued at approximately $9,053,274.81. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James W. Green purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was bought at an average price of $3.07 per share, with a total value of $61,400.00. Following the transaction, the chief executive officer now owns 3,101,091 shares of the company’s stock, valued at approximately $9,520,349.37. The disclosure for this purchase can be found here. Insiders own 9.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD purchased a new position in shares of Harvard Bioscience during the first quarter valued at approximately $54,000. Hillsdale Investment Management Inc. purchased a new position in shares of Harvard Bioscience during the first quarter valued at approximately $112,000. Vanguard Group Inc. boosted its position in shares of Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after buying an additional 49,576 shares during the period. Heartland Advisors Inc. boosted its position in shares of Harvard Bioscience by 2.6% during the first quarter. Heartland Advisors Inc. now owns 889,133 shares of the medical instruments supplier’s stock valued at $3,770,000 after buying an additional 22,666 shares during the period. Finally, AMH Equity Ltd boosted its holdings in shares of Harvard Bioscience by 7.5% in the first quarter. AMH Equity Ltd now owns 2,324,200 shares of the medical instruments supplier’s stock valued at $9,855,000 after purchasing an additional 161,307 shares during the period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Further Reading

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.